Tudor Investment Corp ET AL Acquires Shares of 19,854 Vericel Corporation $VCEL

Tudor Investment Corp ET AL acquired a new stake in Vericel Corporation (NASDAQ:VCEL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 19,854 shares of the biotechnology company’s stock, valued at approximately $625,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Huntington National Bank raised its stake in Vericel by 51.3% in the 3rd quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 273 shares during the period. Abich Financial Wealth Management LLC bought a new position in Vericel during the third quarter worth $31,000. AlphaQuest LLC boosted its position in Vericel by 135.6% during the third quarter. AlphaQuest LLC now owns 3,332 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,918 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Vericel by 13.7% in the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 353 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Vericel by 178.4% in the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,077 shares during the last quarter.

Wall Street Analyst Weigh In

VCEL has been the subject of a number of research reports. Leerink Partners restated an “outperform” rating and set a $46.00 target price on shares of Vericel in a research note on Tuesday, March 10th. Truist Financial lowered their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday. HC Wainwright upped their target price on Vericel from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Vericel Stock Performance

Shares of Vericel stock opened at $32.17 on Wednesday. The firm has a 50-day moving average of $34.95 and a 200-day moving average of $35.77. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $45.97. The stock has a market cap of $1.64 billion, a PE ratio of 103.77 and a beta of 1.22.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, hitting analysts’ consensus estimates of $0.45. The business had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. Vericel’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period last year, the firm earned $0.38 earnings per share. Equities research analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.